Sunitinib for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Author Information
Author(s): Rena Buckstein, John Kuruvilla, Neil Chua, Christina Lee, David A Macdonald, Abdulwahab J Al-Tourah, Alison H Foo, Wendy Walsh, Percy Ivy S, Michael Crump, Elizabeth A Eisenhauer
Primary Institution: Sunnybrook Health Sciences Center
Hypothesis
Does sunitinib provide effective treatment for patients with relapsed or refractory diffuse large B-cell lymphoma?
Conclusion
Sunitinib did not show any objective responses in patients with relapsed or refractory diffuse large B-cell lymphoma and resulted in significant hematologic toxicity.
Supporting Evidence
- No objective responses were seen in the study.
- Nine patients achieved stable disease with a median duration of 3.4 months.
- Grades 3-4 neutropenia and thrombocytopenia were observed in 29% and 35% of patients, respectively.
Takeaway
Doctors tested a medicine called sunitinib to see if it could help people with a type of blood cancer, but it didn't work and made some people feel very sick.
Methodology
This was a non-randomized, non-blinded multi-center phase II trial where patients took sunitinib 37.5 mg orally once daily.
Limitations
The study was closed early due to lack of responses and high toxicity, limiting the ability to draw definitive conclusions.
Participant Demographics
The median age of participants was 65 years, with a mix of male and female patients.
Statistical Information
Confidence Interval
95% CI 1.41-3.48
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website